Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23363400 | 0.83 | PDE2A (0.41) | — | |
| SCHEMBL29757459 | 0.83 | PDE2A (0.41) | — | |
| SCHEMBL5748896 | 0.77 | LMNA (0.38) | LMNAGABRA1GABRB1 | |
| SCHEMBL4734695 | 0.77 | EIF4A3 (0.32) | LMNAGABRA1GABRB1EIF4A3 | |
| SCHEMBL14558054 | 0.76 | LMNA (0.33) | LMNAGABRA1GABRB1 | |
| SCHEMBL12263281 | 0.76 | LMNA (0.34) | LMNAGABRA1GABRB1EIF4A3 | |
| SCHEMBL12434313 | 0.76 | EIF4A3 (0.31) | LMNAGABRA1GABRB1EIF4A3 | |
| SCHEMBL14558319 | 0.76 | CCR1 (0.37) | LMNAGABRA1GABRB1 | |
| SCHEMBL25053869 | 0.75 | PDE2A (0.42) | LMNA | |
| SCHEMBL23022446 | 0.74 | NOS2 (0.37) | LMNAGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| WO-2021178841-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | JANPIX, LTD. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10947259-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3611165-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LMNA 1484/4885GABRA1 1516/4885GABRB1 1692/4885 |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | LMNA 4786/4885GABRA1 3590/4885GABRB1 3001/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | LMNA 4768/4885GABRA1 3193/4885GABRB1 2312/4885 |
| US-10947259-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LMNA 1162/4885GABRA1 1718/4885GABRB1 2239/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | LMNA 3703/4885GABRA1 2605/4885GABRB1 1765/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | LMNA 3781/4885GABRA1 1992/4885GABRB1 905/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LMNA 1162/4885GABRA1 1718/4885GABRB1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.